Benchmark Reiterates Speculative Buy Rating on Intensity Therapeutics, Inc. (INTS) May 20, 2026 09:37AM
Intensity Therapeutics, Inc. (INTS) Misses Q1 EPS by 90c May 7, 2026 04:47PM
Intensity Therapeutics receives US patent for cancer treatment method Mar 24, 2026 08:01AM
Intensity Therapeutics reports 2025 milestones and 2026 plans Jan 13, 2026 07:48AM
Intensity Therapeutics gets 180-day Nasdaq extension until June 2026 Dec 5, 2025 07:30AM


Nov 7, 2025 04:41PM Intensity Therapeutics, Inc. (INTS) Reports In-Line Q3 EPS
Oct 30, 2025 07:30AM Intensity Therapeutics publishes INT230-6 cancer treatment study results
Sep 10, 2025 07:47AM Intensity Therapeutics pauses breast cancer trial enrollment due to skin irritation
Aug 20, 2025 07:37AM Intensity Therapeutics, Inc. (INTS) PT Lowered to $1.50 at Benchmark
Aug 12, 2025 03:16PM Brookline Capital Markets Upgrades Intensity Therapeutics, Inc. (INTS) to Buy
Aug 4, 2025 07:47AM Intensity Therapeutics raises $6.6 million through ATM stock sales
Jun 12, 2025 05:00AM Intensity Therapeutics (INTS) Prices 6.675M Share Offering at $0.30/sh
Jun 11, 2025 04:07PM Intensity Therapeutics (INTS) Announces Proposed Share Offering
Jun 11, 2025 08:34AM Intensity Therapeutics (INTS) announces positive results on INT230-6 amid phase 2
May 21, 2025 08:48AM Benchmark Reiterates Speculative Buy Rating on Intensity Therapeutics, Inc. (INTS)
May 19, 2025 11:32AM Brookline Capital Markets Downgrades Intensity Therapeutics, Inc. (INTS) to Hold
May 13, 2025 04:10PM Intensity Therapeutics, Inc. (INTS) Misses Q1 EPS by 4c
Apr 25, 2025 08:00AM Intensity Therapeutics (INTS) Announces 3.13M Share Offering at $0.85/sh
Mar 19, 2025 07:34AM Benchmark Reiterates Speculative Buy Rating on Intensity Therapeutics, Inc. (INTS)
Mar 13, 2025 04:15PM Intensity Therapeutics, Inc. (INTS) Reports FY Loss of $1.17
Jan 28, 2025 08:03AM Intensity Therapeutics (INTS) Announces Drug Monitoring Committee Authorized Continuation of Ongoing Phase 3 Sarcoma Trial
Dec 13, 2024 04:03PM Intensity Therapeutics (INTS) Files for 1.24M Share Offering by Selling Stockholders
Nov 21, 2024 08:04AM Intensity Therapeutics (INTS) Announces Pricing of $3 Million Registered Direct Offering and Concurrent Private Placement
Nov 18, 2024 08:00AM Intensity Therapeutics (INTS) Presents INT230-6 Phase 1/2 Data in Sarcoma and an Overview of its Ongoing Global Randomized Phase 3 Sarcoma Trial
Sep 20, 2024 12:01PM Brookline Capital Markets Starts Intensity Therapeutics, Inc. (INTS) at Buy, PT $15
Aug 9, 2024 08:26AM Intensity Therapeutics, Inc. (INTS) Misses Q2 EPS by 4c